OrganiGram’s CEO Is Leaving: Newsworthy or Noise?

With the departure of OrganiGram’s (TSX:OGI)(NYSE:OGI) CEO, investors may wonder if they need to pay attention.

| More on:
calculate and analyze stock

Image source: Getty Images

OrganiGram (TSX:OGI)(NASDAQ:OGI) has been a favourite pick of investors who have been watching cannabis stocks. Recently, OrganiGram has been in the purview of investors primarily for good reasons. The company’s surging stock price and ability to capitalize on value-added products has provided mostly positive stories over the past year.

However, of late, OrganiGram has been in the news. This time, the buzz is around CEO Greg Engel, “stepping away” from his designation in OrganiGram.

Indeed, the news has stirred some investors, as the stock plummeted by 5% following the news. However, I don’t think it is going to be that big of the deal moving ahead.

Here’s why I think Greg Engel’s departure is not necessarily newsworthy and why the noise surrounding it could disappear soon.

The ties are not entirely severed

After a four-and-a-half year tenure, the CEO of OrganiGram has decided to part ways from the company and its managerial responsibilities.

However, that does not bring an end to Greg’s role in OrganiGram. As per OrganiGram, he is going to continue as a valued member of its advisory board.

Of course, his innovative leadership and proficiency have helped OrganiGram scale to new heights in the marketplace. Accordingly, some investors have been wary of the change.

That said, the past few years have shown a pattern with organizational changes. Various high-profile CEOs have stepped down or been let go. It appears to be part of the maturing process of this sector.

Accordingly, I think OrganiGram’s operations will remain undeterred from this singular event. The company’s been headed on the right track and has made a series of moves I view as positive for the cannabis player’s long-term growth objectives.

OrganiGram’s growth-by-acquisition strategy

Organigram has been making deals of late that position the company well for long-term growth.

A high-profile deal with British American Tobacco (NYSE:BTI) has sparked interest in this relatively small-cap cannabis player. Indeed, if OrganiGram can integrate its operations and business model with that of BTI, the company’s growth trajectory could change substantially for the better.

Additionally, its recent acquisition of The Edibles & Infusions Corporation deserves consideration. I think edibles is a key growth area that’s relatively under the radar right now. If OrganiGram can become a leader in this space, long-term profit margins could improve substantially.

Additionally, I like the way this deal is structured. The deal has various milestone considerations. Upon the achievement of specific targets, consideration will be paid over time, providing company investors with assurances the company didn’t overpay for this deal. I like that.

Bottom line

OrganiGram is a relatively small cannabis player in the Canadian market, with a market cap of less than $1 billion.

That said, this company is one of the best positioned for growth in terms of its recent acquisitions and strategic shifts.

Accordingly, for those looking to put a few dollars on this sector, OrganiGram is an intriguing choice. It’s not a company I’d bet the farm on, but its growth prospects do look enticing from here.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends OrganiGram Holdings. The Motley Fool recommends OrganiGram Holdings.

More on Cannabis Stocks

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »